Sat.Oct 10, 2020 - Fri.Oct 16, 2020

article thumbnail

Early signs of survival benefit raise optimism around a small biotech's ALS drug

Bio Pharma Dive

Newly published data show that, after joining a clinical trial, patients who were given a drug from Amylyx Pharmaceutcials lived a median 6.5 months longer than those who didn't.

article thumbnail

Get ready for HUGE healthcare changes

World of DTC Marketing

WHAT? There is going to be more coverage for virtual doctors’ visits in new employee health plans along with expanded mental health benefits and access to on-site health clinics. Of course, this comes at an increased cost even though health insurers are making a lot of money. Employees for the most part are happy with their health insurance but that happiness is going to come at a higher cost.

Doctor 207
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

In the News: September Regulatory and Development Updates

Camargo

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. FDA Establishes Digital Health Center of Excellence. The FDA announced the launch of its Digital Health Center of Excellence (DHCoE) on September 22, marking an important step in its efforts to modernize digital health policies and regulatory approaches.

article thumbnail

A Dose of Optimism, as the Pandemic Rages On

NY Times

The months ahead will be difficult. But the medical cavalry is coming, and the rest of us know what we need to do.

145
145
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

5 questions ahead of next week's FDA meeting on coronavirus vaccines

Bio Pharma Dive

Normally staid affairs, next Thursday's advisory committee meeting could be historic and set expectations for how the FDA will approach any future vaccine approval.

Vaccine 348
article thumbnail

AZ’s long-acting COVID-19 antibody moves into phase III

Pharma Times

Two trials will involve over 6,000 participants at sites in and outside the US

Antibody 135

More Trending

article thumbnail

Remdesivir Fails to Prevent Covid-19 Deaths in Huge Trial

NY Times

An antiviral widely used to treat hospitalized patients did not lower the mortality rate in a multinational trial.

Trials 145
article thumbnail

Roche, aiming to make better gene therapies, turns to an emerging startup

Bio Pharma Dive

The Swiss pharma is the third large drugmaker to partner with Harvard spinout Dyno Therapeutics, a small biotech aiming to improve gene therapy technology.

article thumbnail

BMS’ Zeposia hits the mark in ulcerative colitis

Pharma Times

Oral S1P receptor modulator hit both primary endpoints in a phase III trial

Trials 135
article thumbnail

Accelerating the digital approval process

pharmaphorum

The boom in digital tech over COVID means that pharma can move faster than ever – but the industry’s traditional processes for asset approval are still holding timelines back. David Reily examines how pharma companies are responding to the increased burden of asset approval with new ways of working. The coronavirus pandemic has forced a traditionally risk-averse industry tied to legacy systems for regulation and compliance to fully embrace digital solutions in commercial and marketing functions.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Treatment for Histoplasmosis

Pharma Mirror

Histoplasmosis is an inflammatory lung infection that usually occurs when a human has had contact with bird or bat droppings. Histoplasmosis is similar in symptoms to COVID-19, such as shortness of breath, fever, chest pain, and coughing. Some people who are at high-risk for histoplasmosis may also be concerned that they have contracted COVID-19. Though.

130
130
article thumbnail

Vertex faces first notable setback as it pushes beyond cystic fibrosis

Bio Pharma Dive

Safety signals in a mid-stage study led Vertex to stop work on one of its experimental drugs for the inherited disorder alpha-1 antitrypsin deficiency.

Drugs 339
article thumbnail

Sanofi’s Dupixent reduces severe asthma attacks in children

Pharma Times

Biologic therapy hit primary and all key secondary endpoints in phase III

134
134
article thumbnail

Relief Therapeutics and NeuroRx Release Promising Data for Potential COVID-19 Treatment

BioSpace

Relief Therapeutics and NeuroRx released results on Tuesday from their open-label prospective study looking into RLF-100 (aviptadil) as a potential treatment for COVID-19 and respiratory failure.

125
125
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Boehringer, Yale trial digital tech in heart failure

pharmaphorum

Patients with heart failure often have a dismal prognosis as the condition usually worsens over time, but a new study aims to see if digital health technologies can improve their prospects. The trial – run by Boehringer Ingelheim and Yale University – will test a smart bathroom scale device that has cardiac monitoring built in, as well as an app to help patients improve their diet and lose weight and a digital assistant designed to motivate them to actively manage their health.

Trials 121
article thumbnail

Gilead's COVID-19 drug doesn't prevent deaths, large WHO study finds

Bio Pharma Dive

The results could weaken the case for widely using Veklury, also known as remdesivir, just as the company is asking for full approval from the FDA.

Drugs 306
article thumbnail

NICE recommends Novartis’ Mayzent on the heels of SMC approval

Pharma Times

Drug is licensed for secondary progressive multiple sclerosis with active disease

Licensing 125
article thumbnail

U.S. Government Inks Antibody Cocktail Deal with AstraZeneca

BioSpace

AstraZeneca signed a deal with Operation Warp Speed, the U.S. government program to advance COVID-19 vaccines and therapeutics, for a monoclonal antibody cocktail.

Antibody 123
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Pharma and insurers raking in the cash

World of DTC Marketing

HEY NOW : Most companies struggled in the second quarter as the coronavirus pandemic froze the economy, but health insurers like UnitedHealth heavily benefited as people held off on going to the doctor or hospital, resulting in fewer medical claims that needed to be paid. In addition, pharma profit margins remain very high. UnitedHealth Group registered more than $6.6 billion in profits in the second quarter — by far the conglomerate’s highest quarterly profit ever, according to an ana

article thumbnail

J&J halts studies of coronavirus vaccine due to participant's illness

Bio Pharma Dive

The company did not disclose details, nor could it confirm whether the participant had received its shot. But J&J is now the second vaccine developer, along with AstraZeneca, to suspend testing for a safety review.

Vaccine 299
article thumbnail

NIHR review identifies long-term effects of COVID-19

Pharma Times

Review draws on experiences of patients and expert consensus

123
123
article thumbnail

CPhI: Dramatic changes ahead for the generics market

Outsourcing Pharma

Technology impacting generic drugs include artificial intelligence, telemedicine, fraud-preventing digital solutions and more, according to a report.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Innovation boosts R&D outlook despite COVID difficulties – report

pharmaphorum

Ayming Group’s second annual International Innovation Barometer (IIB) has said that the international outlook for R&D is “remarkably promising” despite strong headwinds caused by COVID-19. The report reveals that R&D departments are being empowered by the creation of ‘innovation ecosystems’, new funding methods, and the deployment of technology.

article thumbnail

Pfizer won't seek FDA clearance of coronavirus vaccine until mid-November, CEO says

Bio Pharma Dive

An unusual letter from Pfizer chief Albert Bourla confirms that the drugmaker won't file for an approval of its experimental shot, assuming positive results, before the U.S. presidential election.

Vaccine 279
article thumbnail

Bavencio, Imbruvica among latest SMC decisions

Pharma Times

The committee accepted a number of drugs through the PACE process

Drugs 123
article thumbnail

Operation Warp Speed Boss Projects COVID-19 Vaccine EUA by Thanksgiving

BioSpace

Moncef Slaoui, the head of Operation Warp Speed, suggested the first Emergency Use Authorization for a COVID-19 vaccine will likely be around Thanksgiving.

Vaccine 115
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

UK joins global trial to test BCG vaccine against COVID-19

BioPharma Reporter

A global trial, designed to test the theory that the BCG vaccine could help protect against COVID-19, will soon start recruitment in the UK.

Vaccine 115
article thumbnail

There is value to patients when independent sites offer clinical trials

Bio Pharma Dive

We observe that the COVID-19 crisis shines a light on the benefits to patients and industry stakeholders of bringing clinical trials closer to patients' homes.

article thumbnail

RPS calls for prevention of counterfeit medicines in UK’s supply chain

Pharma Times

In a letter to Health Secretary Matt Hancock the RPS called for urgent action

Medicine 123
article thumbnail

CDC Finalizes COVID-19 Vaccine Distribution Plan as Vaccine Authorization Nears

BioSpace

With multiple COVID-19 vaccines in development, the CDC is confident that any vaccines the FDA authorizes or approves will be safe because they are based on the FDA’s usual stringent protocols. The greater question, after a vaccine is approved, is how it will be distributed.

Vaccine 114
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.